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There exists a varying level of evidence linking the use of antidepressant medication to
the parasomnias, ranging from larger, more comprehensive studies in the area of REM
sleep behavior disorder to primarily case reports in the NREM parasomnias. As such, prac-
tice guidelines are lacking regarding speciﬁc direction to the clinician who may be faced
with a patient who has developed a parasomnia that appears to be temporally related to
use of an antidepressant. In general, knowledge of the mechanisms of action of the med-
ications, particularly with regard to the impact on sleep architecture, can provide some
guidance. There is a potential for selective serotonin reuptake inhibitors, tricyclic antide-
pressants, and serotonin–norepinephrine reuptake inhibitors to suppress REM, as well
as the anticholinergic properties of the individual drugs to further disturb normal sleep
architecture.
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INTRODUCTION
Parasomnias are a diagnostic grouping of sleep disorders that
include abnormal sleep-related behaviors, dreams, or autonomic
changes thatmanifest during transitions fromwakefulness to sleep,
or within transitions between sleep stages. Parasomnia suffer-
ers may complain of unwanted interruptions from sleep, injury
to themselves, or to their bed partner during periods of motor
activation, and dysphoria relating to the burden of shoulder-
ing these negative sequelae. The International Classiﬁcation of
Sleep Disorders categorizes parasomnias into (1) disorders of
arousal from NREM (non-rapid eye movement) sleep – these
include somnambulism, confusional arousals, and sleep terrors;
(2) disorders of REM (rapid eye movement) sleep – these include
REM sleep behavior disorder (RBD), nightmares, and recur-
rent isolated sleep paralysis; and (3) other parasomnias – these
include sleep-related dissociative disorder, sleep enuresis, explod-
ing head syndrome, catathrenia or sleep groaning, hypnagogic or
hypnopompic hallucinations, sleep-related eating disorders, and
parasomnias due to drug, other substance, or medical condi-
tion (Table 1 – note not all of the parasomnias are discussed
in this article given limited existing literature; American Acad-
emy of Sleep Medicine, 2005). Etiologies of the parasomnias vary
based upon diagnoses, although some research has suggested cor-
relations between speciﬁc parasomnias and psychiatric disorders
(Ohayon et al., 1999; Winkelman et al., 1999). This relationship
becomes less clear with the realization that some of the med-
ications used to treat psychiatric disorders may themselves be
linked to the onset of parasomnias. The literature supports an
association between antidepressant pharmacotherapy and certain
parasomnias, with the greatest amount of data for RBD (Olson
et al., 2000; Winkelman and James, 2004; Teman et al., 2009)
and with some data for NREM disorders such as somnambulism
and night terrors (Ohayon et al., 1999; Yeh et al., 2009). Reports
also link sleep-related eating disorder (Winkelman et al., 1999)
to antidepressant use. This review will focus on the association
and proposed mechanisms of action of selective serotonin reup-
take inhibitors (SSRIs), the serotonin–norepinephrine reuptake
inhibitors (SNRIs), the tricyclic antidepressants (TCAs), and the
norepinephrine–dopamine reuptake inhibitor bupropion to para-
somnias. Literature for this review was obtained via systematic
search in PubMed for articles published on or before August 15,
2010. The terms “antidepressants,”“parasomnias,”“SSRI,”“SNRI,”
“bupropion,” “REM behavior disorder,” “nightmares,” “somnam-
bulism,” “confusional arousals,” “sleep terrors,” “sleep paralysis,”
“hypnagogic hallucinations,” and “hypnopompic hallucinations”
were used. References from relevant articles, as well as from recent
reviews of the literature, were also assessed.
The reader will also note that the speciﬁc effects of antidepres-
sants on the sleep-related movement disorders are not the focus of
this parasomnia-centered review, although there is evidence that
speciﬁc antidepressants may induce restless legs syndrome and/or
periodic limb movements of sleep. A review of the most recent
literature on this topic is provided in the references (Hoque and
Chesson, 2010).
THE SSRIs
DEPRESSION AND SLEEP ARCHITECTURE
Major depressionhas been studiedbypolysomnography,withdoc-
umentation of decreased sleep continuity, prolonged sleep onset
latency, increased wake time after sleep onset, decreased sleep
efﬁciency, decreased total sleep time, early morning awakenings,
reductions in slowwave sleep, andREMsleep disturbances (Kupfer
et al., 1986; Benca et al., 1992). Reduced REM sleep onset latency,
increased REM density, and prolonged time spent in ﬁrst REM
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Table 1 | ICSD-II parasomnias.
Disorders of Arousal (From Non-Rapid Eye Movement Sleep)
1. Confusional arousals
2. Sleepwalking
3. Night terrors
Parasomnias Usually AssociatedWith REM Sleep
1. REM sleep behavior disorder (including parasomnia overlap disorder and
status dissociatus)
2. Recurrent isolated sleep paralysis
3. Nightmare disorder
Other Parasomnias
1. Sleep-related dissociative disorder
2. Sleep Enuresis
3. Sleep-related groaning (catathrenia)
4. Exploding head syndrome
5. Sleep-related hallucinations
6. Sleep-related eating disorder
7. Parasomnia, unspeciﬁed
8. Parasomnia due to drug or substance
9. Parasomnia due to medical condition
International classiﬁcation of sleep disorders, 2nd edition.
sleep period have been described in depressed patients (Kupfer
et al., 1981). Several hypotheses have been proposed, including a
relative deﬁciency in sleep homeostasis (sleep drive) with a shifting
forward of the circadian cycle (Borbely and Wirz-Justice, 1982),
versus alterations in cholinergic, serotonergic, and noradrenergic
neurotransmission typically seen in subjects with mood disorders
(Thase, 1998). Further detailing of the causes of sleep changes in
mood disorders is beyond the scope of this review, but may be
found elsewhere in the literature.
ANTIDEPRESSANTS AND SLEEP ARCHITECTURE
Selective serotonin reuptake inhibitors
Serotonin neurons, originating from the dorsal raphe nucleus,
project to the cholinergic laterodorsal and pedunculopontine
tegmental areas, inhibiting “REM-on” neurons and therefore,
inhibiting REM sleep (McCarley and Hobson, 1975; McCarley
et al., 1995). In addition to their tendency to suppress REM sleep,
SSRIs have also been implicated in sleep fragmentation (Sharp-
ley and Cowen, 1995). Despite these effects on sleep architecture,
SSRI treatment of depression may result in an improvement of
sleep symptoms in many patients. Some practitioners opt to add
the medication trazodone (which improves sleep efﬁciency and
decreases sleep onset latency) as a counter to some of the undesir-
able sleep changes that may result from SSRI monotherapy (Van
Bemmel et al., 1992). Trazodone is a 5-HT2A receptor antagonist
that weakly inhibits the 5-HT2C receptor; its sedative proper-
ties may be due to its potent α1-adrenergic blockage (Asayesh,
1986). Finally, a distinctive effect of the SSRI ﬂuoxetine has been
described on the polysomnogram (PSG). The term “Prozac eyes”
has been used to describe eye movements occurring during all
stages of NREM sleep (Armitage et al., 1995a), although the sig-
niﬁcance of this alteration in the PSG is unknown. Of note,
this effect is not exclusive to ﬂuoxetine and has been reported
with other SSRIs, including paroxetine, sertraline, citalopram, and
escitalopram (Geyer et al., 2009).
TCAs and SNRIs
The neurophysiologic effect of REM sleep suppression has been
observed with TCAs (Kupfer and Spiker, 1982; Armitage, 1996).
TCAs (and SNRIs) act predominantly as serotonin and norepi-
nephrine reuptake inhibitors. As serotonergic agents, they might
be expected to affect sleep similar to SSRIs. In addition, norepi-
nephrine, originating from the locus ceruleus, has an inhibitory
effect on pontine “REM-on” neurons (Semba, 1993). The TCAs,
more so than the SNRIs, also have anticholinergic properties of
varying degree and contribute to the reduction of REM sleep on
this basis (possibly by reducing the effects of acetylcholine in the
basal forebrain duringREMsleep).Acetylcholine potentiates REM
via activation of“REM-on”cells in the pontine tegmentum(Berger
and Riemann, 1993). Further sleep-related effects of the TCAs
occur through their antagonism at histamine receptors (primarily
H1 and H2). Central histamine at H1 and H2 receptors is wake-
promoting, and inactivation has been shown in animal models to
result in an increase in NREM sleep (Lin et al., 1988).
Bupropion
Bupropion may reduce REM less than other antidepressants.
Bupropion prolongs REMsleep latency and increases REMdensity
(a measure of the number of eye movements in the period) and
activity during the ﬁrst REM sleep period (Ott et al., 2004). Oth-
ers have found an increase in overall REM sleep percentage with
bupropion (Nofzinger et al., 1995). Bupropion’s primary mecha-
nism is thought to be via action as a dopamine reuptake inhibitor,
though it also acts as a norepinephrine receptor antagonist (Ascher
et al., 1995). Its lack of REM sleep suppression may be due to
absence of an effect on serotonin reuptake.
SSRIs AND REM SLEEP-RELATED PARASOMNIAS
Patients with depression frequently have disturbances in REM
sleep. SSRIs are known to suppress REM, but are regularly used
to treat depression. Given these facts, it is not surprising that
REM sleep-related events including parasomnias may occur in
depressed patients being treated with SSRIs. A recent cross-
sectional study published by Lam et al. (2008) found a higher
percentage of RBD in subjects with depressive spectrum disor-
ders who were taking SSRIs. The authors prospectively identiﬁed
patients with parasomnias using a structured questionnaire, and
then conﬁrmed diagnoses via clinical interview and PSG for those
with recent active parasomnias. Of the 1235 subjects who com-
pleted diagnostic interview, 276 (22.3%) were positive for som-
nambulism, sleep-related eating disorder, or sleep-related injury,
with the latter including REM-related parasomnia as primary
cause of injury (66.6%of the 70 subjects with sleep-related injury).
REM-related parasomnias included RBD, nightmares, and mixed
REM and NREM parasomnias. Sleep violence was correlated with
depressive spectrum disorder (78.3% of those with depressive
spectrum disorder) but no association was found with bipolar
or anxiety spectrum disorders. SSRI use was associated with vivid
dream recall and loss of REM atonia on PSG in the psychiatric
population studied. Subjects taking SSRIs had increased risk of
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having an active RBD-like disorder (OR = 3.7, 95% CI= 1.6–8.7,
p< 0.05) and 5% of those subjects taking SSRIs reported symp-
toms of RBD. Interestingly, the subjects in this study were younger
and included more females than are typically associated with
the usual demographic for RBD, leading the authors to suggest
that psychotropic-related RBD may present in those without the
expected characteristics of old age, male predominance, or asso-
ciation with α-synucleinopathy. Further, the authors posited that
these psychiatric subjects may have been vulnerable to “recurrent
emotionally charged and aggressive dreams” and were perhaps
more likely to enact RBD-like behaviors in the face of loss of REM
atonia. Future studies may help clarify the relationship between
drug-related RBD and typical RBD, including the mechanisms
underlying each.
Other authors have found a link between SSRI use and the
development of RBD symptoms in subjects without knownunder-
lying neurodegenerative disease, though study designs differ,
and case reports predominate over higher-level methodologies
(Schenck et al., 1992; Winkelman and James, 2004). Teman et al.
(2009) performed a retrospective case–control chart review in
which 48 idiopathic RBD patients were divided into groups based
upon age of onset, then were compared to each other and to con-
trols. Early onset RBD patients had signiﬁcantly more psychiatric
diagnoses (OR= 17.0) and antidepressant use (OR= 12.0) than
did controls, while late-onset RBD sufferers had similar increase
in psychiatric diagnoses without a signiﬁcant increase in antide-
pressant use. There were more females in the early onset group.
Similar to Lam et al. (2008) the authors suggested that there may
be different clinical RBD proﬁles relative to psychiatric diagnoses,
antidepressant use, and age. This may indicate that antidepressant
medications contribute independently to RBD onset, particularly
in younger patients. As a result, the clinician who is presented with
a case of RBD in a younger, female patient may be alerted to screen
for antidepressant medications as a possible etiology. In an earlier
study, Schenck et al. (1992) retrospectively reviewed 2650 PSG
reports to identify those treated with ﬂuoxetine or TCAs, ﬁnding
in the data a case of ﬂuoxetine-induced RBD that resolved when
the medication was discontinued. In addition, there exists one
case report of the SSRI paroxetine associated with RBD at a 30-mg
dose (Parish, 2007), though an earlier case series (Yamamoto et al.,
2006) found improvement in RBD symptoms from paroxetine in
16 out of 19 participants, with possible REM sleep suppression
effects as the causal mechanism cited.
Inorder tobetter clarify the relationshipbetweenRBDandanti-
depressant use, Winkelman and James (2004) performed a chart
review that compared clinical and PSG data of 15 subjects taking
serotonergic antidepressants with 15 subjects in an age-matched
control group without a depressive or anxiety disorder that was
not taking these medications. The antidepressant group exhibited
increased tonic submental electromyogram (EMG) activity dur-
ing REM sleep compared to controls. The authors hypothesized an
effect of serotonin on motor systems at the spinal cord or brain-
stem as a possible mechanism. As this study was retrospective and
the control group patients did not have a depressive or anxiety
disorder, it is difﬁcult to separate the effects of SSRIs from the
effects of such underlying disorders. For example, the relation-
ship of RBD with the synucleinopathies, including Parkinson’s
disease, multiple system atrophy, and dementia with Lewy Bodies,
leaves open the possibility that psychiatric symptoms may pre-
dict a later neurologic disorder, an observation noted by Teman
et al. (2009). Teman cites several studies that demonstrate the asso-
ciation between depression and Parkinson’s disease (Lieberman,
2006) as well as the correlation between RBD and later identiﬁ-
cation of neurodegenerative disorders (Schenk et al., 1996, 2003;
Olson et al., 2000; Boeve et al., 2003). Literature on antidepressants
and RBD are provided in Table 2.
Nightmares are a REM-related parasomnia for which a link
to SSRIs has been studied (Table 3). Earlier research demon-
strated a relationship between SSRI use and dreaming in general,
with some studies ﬁnding enhancement of dreams with citalo-
pram (Koponen et al., 1997) and ﬂuoxetine (Markowitz, 1991;
Armitage et al., 1995b; Lepkifker et al., 1995). Pace-Schott et al.
(2001) examined the dream effects of paroxetine and ﬂuvoxam-
ine in 14 normal subjects who were randomized to one of the
drugs during 19 days of a 31-day home-based study. While dream
recall frequency was diminished during the treatment period, sub-
jective report of dreams indicated increased intensity of dreams
during both treatment and acute discontinuation. The authors
acknowledge that this effect seemed to run counter to the well-
known effects of REM sleep suppression by SSRIs, and offer that
enhanced brain arousal may be associated with aminergic stim-
ulation. They cite a possible difference in processes involved in
dream initiation and the quality and/or maintenance of already-
occurring dreams, pointing to research by Nofzinger et al. (1995)
which found an increase in phasic REM activity with ﬂuoxetine
use. An alternative hypothesis by the authors is that late-night
cholinergic rebound after serotonergic REM sleep suppression
earlier in the night may result in greater dream intensity being
reported. The authors acknowledge that patient reports of wors-
ened nightmares with SSRIs are difﬁcult to study, given the
complex relationship of depression-related REM enhancement,
drug-related REM sleep suppression, depression-related dream
suppression, and recovery-related dream enhancement. Further
research is needed to elucidate the mechanisms governing these
interrelated systems.
SSRIs AND REM-RELATED PARASOMNIAS: CLINICAL GUIDELINES
No formal clinical guidelines exist for the use of SSRIs in RBD,
though there is mention of an adverse relationship in the Best
Practice Guide for the Treatment of RBD published by the Stan-
dards of Practice Committee of the AASM (Aurora et al., 2010a).
Data supporting SSRIs as a possible cause of secondary RBD is pre-
sented, though no guidance on treatment is provided. Paroxetine
in particular is mentioned, citing the inconclusive data indicat-
ing its potential efﬁcacy in the treatment of RBD. The authors
state that there is little support for such use. A recent review
(Hoque andChesson,2010) of pharmacologically inducedor exac-
erbatedRLS,PLMs,andRBD,however,didﬁnd strong evidence for
drug-induced RBD with the TCA clomipramine, the monoamine
oxidase inhibitors (MAOIs) selegiline and phenelzine, and lower
levels of evidence for the SSRIs. The authors acknowledged that
clinicians might opt to modify treatment given the emergence of
RBD with the use of certain medications, including switch to an
alternativemedication orwithdrawal of themedication if prudent.
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Table 2 | Antidepressants and parasomnia: RBD.
Parasomnia Antidepressant
medication(s)
Reference Methods/design Findings
RBD SSRIs/SNRI, ﬂuoxetine,
paroxetine, citalopram,
sertraline, venlafaxine
Winkelman and James
(2004)
Chart review, n =15 on
SSRIs, n =15 controls, PSG
data included
Antidepressant group had increase in tonic EMG
during REM compared to controls
SSRIs, TCAs, Mixed
Mechanism, bupropion
Teman et al. (2009) Retrospective, case–control,
chart review, 48 idiopathic
RBD patients, compared
with controls
Early onset RBD patients exhibited more psychi-
atric diagnoses [OR=17.0 (3.5–83.4)] and anti-
depressant use [OR-12.0 (2.7–53.3)] than non-
RBD controls
SSRIs, TCAs Olson et al. (2000) Retrospective chart review
of 93 consecutive patients
with RBD
Lack of strong causal relationship between anti-
depressants and RBD, however patient mean
age of RBD onset=60.9, 2 of 11 on antidepres-
sants developed RBD with use of medication
SSRIs Lam et al. (2008), Ott
et al. (2004)
Prospective, cross-sectional
study, n =1235 psychiatric
outpatients; questionnaire,
structured interview, PSG
SSRIs increased RBD risk [OR=3.7 (95%
CI=1.6–8.7, p<0.05)], younger patients, female
patients experienced more medication-related
RBD
SSRI – ﬂuoxetine Schenck et al. (1992),
Nofzinger et al. (1995)
Single case in retrospective
review of n =2650 PSGs
Fluoxetine-induced RBD resolved with discon-
tinuation of medication
SSRI – paroxetine Parish (2007), Lam et al.
(2008)
Case report Paroxetine 30mg was associated with RBD-like
symptoms
SSRI – paroxetine Yamamoto et al. (2006),
Schenck et al. (1992)
Case series; n =19 Paroxetine improved RBD symptoms in 16/19
studied
SSRIs, TCAs, MAOIs Hoque and Chesson
(2010), Markowitz (1991)
Review Higher-level of evidence for TCA- and MAOI-
related RBD than SSRIs
Table 3 | Antidepressants and parasomnia: nightmares.
Parasomnia Antidepressant
medication(s)
Reference Methods/design Findings
Nightmares Fluoxetine Lepkifker et al. (1995),
Schenk et al. (2003)
Case series Four patients experienced nightmares on ﬂuoxetine
monotherapy
Nightmares Bupropion Balon (1996), Gaillard
et al. (1994)
Case report 55-year-old femalewith nightmares following increase
in bupropion from 75 to 150mg/day
Dream
intensity
Fluoxetine,
paroxetine
Pace-Schott et al. (2001),
Armitage et al. (1995b)
14 Normal subjects randomized
to ﬂuoxetine or paroxetine
Subjects reported increase in dream intensity during
SSRI phase
Dream
enhancement
Citalopram Koponen et al. (1997),
Boeve et al. (2003)
Open pilot study Dream enhancement in 6% of subjects
Careful assessment of the risks and beneﬁts of such a move should
occur given the individualized experience of each patient.
Recently, the AASM standards of practice committee published
its Best Practice Guide for the Treatment of Nightmare Disorder
in Adults (Aurora et al., 2010b). These recommendations indicate
that non-SSRI medications such as trazodone, ﬂuvoxamine, and
the TCAs “may be considered for treatment of PTSD-associated
nightmares, but the data are low grade and sparse.”Nefazodone is
also mentioned, but not recommended, due to potential for hepa-
totoxicity. The authors also cite research studying the effect of the
SNRI venlafaxine on PTSD-related nightmares, noting no signif-
icant difference between the medication and placebo. As a result,
venlafaxine is not suggested for the treatment of PTSD-associated
nightmares.
REM-RELATED PARASOMNIAS: OTHER ANTIDEPRESSANTS
Most non-SSRI antidepressants have not been extensively
researched for their role in the genesis of REM-related parasom-
nias. As discussed earlier, those with aminergic properties, such
as the SNRIs, have been thought to behave similarly to SSRIs
due to their inhibitory effect on REM-on neurons in the pons.
The reader is referred to Gaillard et al. (1994) for a further dis-
cussion of this mechanism. As discussed, the TCAs, which have
aminergic properties, have been implicated for their potential to
induce RBD (Mahowald et al., 2007). Anticholinergic effects of
the TCAs may be responsible for reduced cholinergic atonia in
REM sleep (Schenck et al., 1992). Research detailing the effects
of speciﬁc SNRIs or bupropion on REM-related parasomnias,
however, is lacking. In the Teman et al. (2009) study discussed
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earlier, one of the early onset RBD subjects studied was tak-
ing a combination of amitriptyline and paroxetine, and in three
others, bupropion was given in combination with another antide-
pressant. None of the subjects in the late-onset RBD group was
taking bupropion. This data is obviously limited, however, and
no conclusions about the medications and RBD can be made.
There is one case report of bupropion inducing nightmares, with
cessation of the nightmares once the medication was discontin-
ued (Balon, 1996). In total, though, there is not a preponder-
ance of literature describing this phenomena in subjects using
bupropion.
DEPRESSION AND NREM SLEEP PARASOMNIAS
The NREM parasomnias are disorders of arousal from NREM
sleep, with impaired sleep–wake transitions that can result in
activation of physiologic systems. Somnambulism, confusional
arousals, and sleep terrors may occur when the transition from
slowwave sleep towakefulness is disrupted. Research has described
several factors that may contribute to the development of a NREM
parasomnia, including genetic susceptibility, sleep deprivation, sit-
uational stress, psychiatric conditions, medication, and substance
use (Pressman, 2007). NREM sleep abnormalities have been stud-
ied in depressed subjects,with an early study by Buysse et al. (1997)
ﬁnding a shift in slow wave delta activity to the initial part of the
sleep period in depressed subjects following treatment with inter-
personal psychotherapy. Subjects who experienced a recurrence of
depression exhibited less baseline slow wave activity compared to
those still in remission at 1 year follow-up. These ﬁndings suggest
that depressed patients may themselves be predisposed to NREM
sleep disturbance both pre- and mid-treatment Lopes et al. (2007).
performed further research into the nature of NREM sleep distur-
bance in depressed subjects, using analysis of cyclic alternating
pattern (CAP) as a measure of NREM variability. The PSGs of 15
subjects with major depressive disorder were compared to those
of 20 controls. Researchers found depressives had greater distur-
bances in phase A1 of CAP, a period of NREM sleep that may
indicate an impending shift from NREM stage 2 to NREM stage 3
sleep. This study represents one of the ﬁrst attempts to clarify the
nature of speciﬁc NREM sleep disturbance in depressed subjects,
and may point to a relationship between somnambulism, which
tends to occur in the ﬁrst third of the night during the great-
est period of slow wave sleep, and NREM sleep abnormalities in
depressives.
ANTIDEPRESSANTS AND NREM PARASOMNIAS
There are numerous case reports linking speciﬁc antidepres-
sants to the various NREM sleep parasomnias, including reports
of somnambulism with bupropion (Khazaal et al., 2003; Oulis
et al., 2010), the noradrenergic and speciﬁc serotonergic tetra-
cyclic mirtazapine (Yeh et al., 2009), paroxetine (Kawashima and
Yamada, 2003), and the norepinephrine reuptake inhibitor rebox-
etine (Künzel et al., 2004). In contrast, there is one case report
detailing the successful treatment of somnambulism and night
terrors with paroxetine (Lillywhite et al., 1994), and an earlier
report demonstrating efﬁcacy from the tricyclic imipramine (in
combination with diazepam) in the treatment of somnambulism
and night terrors (Cooper, 1987). In the Lam et al. (2008) study
mentioned previously, sedative antidepressants were being used
by 34.5% of the 29 psychiatric subjects who were diagnosed with
somnambulism (p< 0.05). In their study, “sedative antidepres-
sants” included TCAs, trazodone, and the tetracyclic mianserin.
SSRIs, SNRIs, and noradrenergic and speciﬁc serotonergic antide-
pressantswere also used in thosewith somnambulism,butwithout
statistical signiﬁcance. The authors noted that while the TCAs
in particular are not noted for alterations in NREM sleep, their
antihistamine and anticholinergic effects might negatively impact
arousal. Though the topic is not within the scope of this arti-
cle, it can be brieﬂy mentioned that Lam et al. (2008) also found
increased sleepwalking in those using non-benzodiazepine hyp-
notics such as zolpidem and zopiclone, medications thought to
alter slow wave sleep and possibly leading to arousal disturbances
in NREM sleep due to this property. The literature regarding
antidepressants and NREM sleep parasomnia is summarized in
Table 4.
In summary, the literature concerning NREM sleep parasom-
nias and antidepressants is limited, with a number of case reports
that do not as of yet demonstrate a compelling pattern link-
ing the medications used to treat depression with these sleep
disorders. Some of the medications may, in fact, be helpful in
the treatment of NREM parasomnias, though there are no large
randomized controlled studies to support this. NREM sleep para-
somnias may be related to the underlying psychiatric condition,
with depression having been studied for NREM abnormalities that
may predispose one to dysfunctional transitions between sleep
and wake, particularly in the early part of the sleep period. Future
investigations might utilize CAP analysis to better describe the
speciﬁc NREM abnormalities present in depressed subjects, and
determine what pharmacologic interventions may target these
abnormalities.
ANTIDEPRESSANTS AND OTHER PARASOMNIAS
The third category of parasomnias, classiﬁed as “other parasom-
nias,” includes sleep-related dissociative disorder, sleep enuresis,
exploding head syndrome, catathrenia or sleep groaning, hypna-
gogic or hypnopompic hallucinations, sleep-related eating disor-
ders, and parasomnias due to drug, other substance, or medical
condition. Of these, sleep-related eating disorder may have a rela-
tionship to depression in that depressives are frequently treated
with non-benzodiazepines such as zolpidem for insomnia, and
these medications may result in an increase in complex sleep-
related behaviors. Zolpidem has also been studied for its relation-
ship to somnambulism and sleep driving (Hoque and Chesson,
2009). Hwang et al. (2010) studied 125 psychiatric outpatients
taking hypnosedatives, and found that 15.2% reported complex
sleep-related behaviors (including sleep-related eating). Of these,
all were taking zolpidem, and there was a tendency toward younger
age (p = 0.023), female gender (p = 0.011), and use of higher dose
of zolpidem (>10 mg/day; p< 0.001). Sleep-related eating dis-
order must be distinguished from nocturnal eating syndrome, a
disorder typiﬁed by a circadian delay in the timing of eating that
can be effectively treated with the SSRI sertraline (Stunkard et al.,
2006). In sleep-related eating disorder, the patient may not be fully
awake during eating, and may have little or no recall for the event
the next day.
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Table 4 | Antidepressants and NREM parasomnias.
Parasomnia Antidepressant
medication(s)
Reference Methods/design Findings
Somnambulism Mirtazapine Yeh et al. (2009) Case report 40-year-old female with new-onset somnambu-
lism× three nights with increase in mirtazapine
from 30 to 45mg; somnambulism terminated
with cessation of medication
Somnambulism Bupropion Oulis et al. (2010),
Buysse et al. (1997)
Case report 63-year-old female with somnambulism in con-
text of adjunctive bupropion for depression
Somnambulism Bupropion Khazaal et al. (2003),
Lopes et al. (2007)
Case report 33-year-old male using bupropion 150mg BID
for smoking cessation; developed somnam-
bulism and sleep-related eating with use –
resolved with discontinuation
Somnambulism Paroxetine Kawashima andYamada
(2003), Oulis et al. (2010)
Case report 61-year-old female with somnambulism onset
1week after initiation of paroxetine 20mg;
ceased with discontinuation
Somnambulism
night terrors
Paroxetine Lillywhite et al. (1994),
Kawashima andYamada
(2003)
Case report 46-year-old female with somnambulism and
night terrors successfully treated with paroxe-
tine 40mg
Somnambulism Reboxetine (SNRI) Künzel et al. (2004),
Khazaal et al. (2003)
Case report 19-year-old female with depression and history
of somnambulism in childhood had recurrence
with use of reboxetine
Somnambulism “Sedative
antidepressants,”
TCAs, trazodone,
tetracyclic, mianserin
Lam et al. (2008), Ott
et al. (2004)
Prospective, cross-sectional
study, n =1235 psychiatric
outpatients; questionnaire,
structured interview, PSG
Sedative antidepressants being used by
34.5% of the 29 patients with somnambulism
(p<0.05)
Table 5 | Antidepressants and other parasomnias.
Parasomnia Antidepressant
medication(s)
Reference Methods/design Findings
Sleep-related
eating disorder
Unknown Winkelman et al. (1999) n =207 depressed subjects in
antidepressant trial were
administered. The inventory of
nocturnal eating
3.4% of depressed subjects reported symp-
toms of sleep-related eating disorder, thought
to be higher prevalence than that in general
population
Hypnagogic/
hypnopompic
hallucinations
Unknown Ohayon et al. (1996),
Hwang et al. (2010)
n =4972 U.K. community sample
interviewed by telephone about
sleep disturbances
Increase in hypnopompic hallucinations in sub-
jects taking antidepressants [OR=1.4 (95% CI
1–1.9)]
Hypnagogic or hypnopompic hallucinations occur at sleep
onset or awakening and may be associated with psychiatric
disorders. In research by Ohayon et al. (1996) these phenom-
ena were found to occur more frequently than predicted by the
prevalence of narcolepsy, a diagnosis with which hypnagogic
and hypnopompic hallucinations are associated. A community
sample of 4972 subjects underwent a telephone interview that
involved demographic questioning as well as diagnostic analy-
sis of sleep disorders. The subjects were also asked about sleep
habits as well as the presence of psychiatric disorders and the
symptoms associated with them. Subjects with anxiety disor-
ders and depression reported a statistically signiﬁcant higher
rate of sleep-related hallucinations (hypnagogic: anxiety disor-
der OR= 1.4, 95% CI 1.3–1.8; mood disorder OR 1.52, 95%
CI 1.2–1.8 and hypnopompic: anxiety disorder OR 1.4, 95% CI
1.1–1.8, mood disorder OR 1.52, 95% CI 1.2–1.8). Of note, the
authors failed to ﬁnd an association between the presence of
these hallucinations and the use of any psychotropic medica-
tions in the subjects reporting hypnagogic hallucinations, but use
of sleep-inducing, anxiolytic, or antidepressant medication did
predict an increase in hypnopompic hallucinations (OR = 1.4,
95% CI 1.0–1.9). However, as the speciﬁc medications used are
not reported in the article, it is difﬁcult to reach meaningful
conclusions regarding antidepressant use and sleep-related hal-
lucinations. Careful diagnosis is essential, as hallucinations may
be related to RBD, narcolepsy, or other neurologic or psychi-
atric disorder, any of which may have their own propensity to
emerge in the presence of various medications. The literature
regarding antidepressants and other parasomnias is summarized
in Table 5.
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CONCLUSION
There exists a varying level of evidence linking the use of anti-
depressant medication to the parasomnias, ranging from larger,
more comprehensive studies in the area of RBD to primarily
case reports in the NREM parasomnias. As such, practice guide-
lines are lacking regarding speciﬁc direction to the clinician who
may be faced with a patient who has developed a parasomnia
that appears to be temporally related to use of an antidepres-
sant. In general, knowledge of the mechanisms of action of the
medications, particularly with regard to the impact on sleep archi-
tecture, can provide some guidance. There is a potential for SSRIs,
TCAs, and SNRIs to suppress REM, as well as the anticholinergic
properties of the individual drugs to further disturb normal sleep
architecture.
New research may suggest patterns of NREM disturbances
associated with depression and the medications used to treat
depression. These abnormalities may result in a disturbance of
the stability of NREM sleep that may predispose to one or more
parasomnias. Understanding the mechanisms that govern the
action of these medications, as well as the pathogenesis of depres-
sion itself, will provide further guidance into the relationship of
antidepressant use and the parasomnias.
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